UNASSIGNED: @entity6715 ( @entity6715 ) and @entity137 ( @entity137 ) are @entity272 with @entity4530 formation accompanied by @entity33 . These conditions are considered to be life-threatening illnesses. Understanding the clinical presentation, risk factors, treatment options and results will be advantageous for physicians in the management of @entity1 in the future. The aim of the present study was to review and analyze the clinical manifestations, drug implications, treatment and outcome of @entity1 with @entity6715 and/or @entity137 who had been hospitalized in a tertiary care center. All hospitalized @entity1 with @entity6715 and/or @entity137 during a 5-year period were retrospectively reviewed. The clinical severity was graded according to the score of @entity137 (SCORTEN) scale. Clinical symptoms, diagnosis, possible precipitating factors, management and outcome data were collected for analysis. A total of 43 @entity1 (mean age, 49.5 years) were hospitalized and classified into the @entity6715 group (55.8%), @entity6715 / @entity137 overlap group (20.9%) and @entity137 group (23.3%). The majority of the @entity1 (90.7%) had @entity203 associated with oral drug administration. @entity208 , anticonvulsants and antibiotics were the most common causative agents for the @entity203 . Twenty-eight @entity1 (65.1%) were treated with @entity288 . The mortality rate was 6.9%. Comparison between the survival group and the non-survival group revealed that @entity1 age >70 years (P=0.014) and body surface area involvement >20% (P<0.01) were the significant factors associated with mortality. The use of systemic @entity230 was higher in the survival group in comparison with the non-survival group (65.1 vs. 0%, respectively; P=0.014). The @entity203 in @entity6715 and @entity137 are mostly caused by medication. With early recognition and treatment, the mortality rate in this study was lower than that in previous reports. @entity1 age and the area of mucocutaneous involvement were significant factors associated with mortality.

Clinical characteristics and treatment outcome of @entity6715 and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['TEN', 'toxic epidermal necrolysis'] @entity6715 :: ('MESH:D013262', 'Disease') :: ['SJS', 'Stevens-Johnson syndrome'] @entity4530 :: ('MESH:D001768', 'Disease') :: ['blister'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucosal involvement'] @entity203 :: ('MESH:D003875', 'Disease') :: ['mucocutaneous eruptions', 'mucocutaneous eruption'] @entity272 :: ('MESH:D012871', 'Disease') :: ['erythematous skin lesions'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity208 :: ('MESH:D000493', 'Chemical') :: ['Allopurinol'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity137 :: (MESH:D064420,Disease) :: ['toxic epidermal necrolysis']
